Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.

@article{Pachmann2008MonitoringTR,
  title={Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.},
  author={Katharina Pachmann and Oumar Camara and Andreas Kavallaris and Sabine Krauspe and Nele Malarski and Mieczyslaw R. Gajda and Torsten Kroll and Cornelia J{\"o}rke and Ulrike Hammer and A. Altendorf-Hofmann and Carola Rabenstein and Ulrich A. Pachmann and Ingo Bernhard Runnebaum and Klaus H{\"o}ffken},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 8},
  pages={
          1208-15
        }
}
  • K. Pachmann, O. Camara, K. Höffken
  • Published 10 March 2008
  • Medicine, Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To demonstrate that it is possible to monitor the response to adjuvant therapy by repeated analysis of circulating epithelial tumor cells (CETCs) and to detect patients early who are at risk of relapse. PATIENTS AND METHODS In 91 nonmetastatic primary breast cancer patients, CETCs were quantified using laser scanning cytometry of anti-epithelial cell adhesion molecule-stained epithelial cells from whole unseparated blood before and during adjuvant chemotherapy. RESULTS Numbers of… 

Figures and Tables from this paper

Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients
TLDR
The reliability of single cell expression analyses in isolated and collected CETC from whole blood samples of patients with early-stage breast cancer before and after radiotherapy (RT) using the maintrac® method was investigated and proved to be feasible.
Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy
TLDR
CTCs can be used as predictors of relapse after definitive treatment of locally advanced breast cancer; however, CTCs detection in peripheral blood during the course of PC does not implicate a particular pattern of response to treatment.
Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy
TLDR
The results show that peripherally circulating tumor cells in patients with advanced NSCLC are influenced by systemic chemotherapy and an increase in spite of therapy is a marker of aggressiveness of the tumor cells.
Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy
TLDR
There is the possibility of preventing further progression by identifying less responsive tumors during NACT using CTC monitoring, which could also be used effectively during adjuvant therapy.
Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy.
TLDR
Results on CTC determination in peripheral blood in non-metastatic breast cancer patients in the context of neoadjuvant treatment show that the persistence of CTCs before and after treatment can identify a subpopulation of patients with an increased risk of recurrence.
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
TLDR
The results suggest the independent prognostic relevance of CTCs both before and after adjuvant chemotherapy in a large prospective trial of patients with primary breast cancer.
Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome
TLDR
It is able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.
Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer
TLDR
Baseline C TCs and maximal CTCs during therapy both seem to be good prognostic markers for OSCC when treated by TPF induction chemotherapy, surgery, and postoperative (chemo)radiation.
Circulating tumor cells in breast cancer
TLDR
Circulating tumor cells might become a valuable tool to refine prognosis in early and metastatic breast cancer and may serve as a real-time tumor biopsy for individually-tailored targeted therapies.
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
TLDR
Analysis of the behavior of CETC can, in the future, contribute to evaluate the efficacy of targeted therapy early during the course of the disease, sparing patients unnecessary treatment but also to reduce the costs for the health system and to downsize the extent and length of clinical studies.
...
...

References

SHOWING 1-10 OF 35 REFERENCES
The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
TLDR
Responsibility of CETC already during the first cycles of neoadjuvant treatment predicts the final response of the tumor.
An increase in cell number at completion of therapy may develop as an indicator of early relapse
TLDR
As in the previous report, Kaplan–Meier analysis revealed a high correlation between the response of CETC to therapy and relapse (p < 0.0001) and curves of both patient groups were super imposable.
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity
TLDR
Circulating tumor cells seem to be nonproliferating cells that persist during chemotherapy and are linked to disease progression and elevated tumor marker concentrations in patients with metastatic breast cancer.
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
TLDR
The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Detection of micrometastatic disease in bone marrow: is it ready for prime time?
TLDR
Until clinically relevant data regarding successful therapy of MRD are available, treatment interventions on the basis of MRd should only be performed within clinical trials.
Standardized quantification of circulating peripheral tumor cells from lung and breast cancer
TLDR
The proposed simple and easy method allows close monitoring, which may help in real-time analysis of the response of solid tumors, especially their systemic component, to therapy and hopefully will contribute to more individually tailored therapy.
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
TLDR
There appears to be a balance between tumor replication and cell death for as long as 22 years in dormancy candidates and it is concluded that this is one mechanism underlying tumor dormancy.
Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells
TLDR
Frequently before but regularly during surgery of breast cancer, epithelial cells are mobilized into circulation, and part of these cells are cleared from the circulation as also shown to occur in benign conditions.
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
TLDR
It is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies, and a lack of standardization means that the results of the individual studies are not directly comparable.
...
...